Stockscreener 앱 받기
37.73
3.08%
-1.20
전일 마감가:
$38.93
열려 있는:
$38.63
하루 거래량:
841.70K
Relative Volume:
0.89
시가총액:
$2.03B
수익:
-
순이익/손실:
$-119.95M
주가수익비율:
-18.75
EPS:
-2.0123
순현금흐름:
$-95.28M
1주 성능:
-1.49%
1개월 성능:
+7.68%
6개월 성능:
+182.20%
1년 성능:
+411.25%
1일 변동 폭
$37.13
$39.30
1주일 범위
$37.10
$40.65
52주 변동 폭
$6.42
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
명칭
Tyra Biosciences Inc
전화
(619) 728-4760
주소
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
37.73 | 2.03B | 0 | -119.95M | -95.28M | -2.0123 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-02-10 | 개시 | William Blair | Outperform |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-05-21 | 재개 | Piper Sandler | Overweight |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-10-18 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-08-15 | 개시 | Piper Sandler | Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-30 | 개시 | Wedbush | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-06-23 | 개시 | H.C. Wainwright | Buy |
| 2022-03-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-10-11 | 개시 | BofA Securities | Buy |
| 2021-10-11 | 개시 | Cowen | Outperform |
| 2021-10-11 | 개시 | Jefferies | Buy |
모두보기
Tyra Biosciences Inc 주식(TYRA)의 최신 뉴스
IPO Launch: Is Tyra Biosciences Incs ROE strong enoughEntry Point & Precise Swing Trade Alerts - baoquankhu1.vn
FMR LLC holds 14.4% of Tyra Biosciences (NASDAQ: TYRA) - stocktitan.net
Tyra Biosciences (NASDAQ:TYRA) Now Covered by Canaccord Genuity Group - Defense World
Canaccord Genuity Group Begins Coverage on Tyra Biosciences (NASDAQ:TYRA) - MarketBeat
Canaccord Genuity Initiates Tyra Bioscience at Buy With $50 Price Target - marketscreener.com
CCORF Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $50 - 富途牛牛
Growth Stocks To Watch Now – April 3rd - Defense World
A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress - finance.yahoo.com
Promising Growth Stocks To Watch Today – April 2nd - defenseworld.net
Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com
Tyra Bioscience Strengthens Financial Leadership with New Officer - TipRanks
Tyra Biosciences (TYRA) VP details multi-year stock option grants - stocktitan.net
Tyra Biosciences names Julia Rueb principal accounting officer, succeeding Alan Fuhrman - TradingView
Tyra Biosciences (NASDAQ: TYRA) taps Julia Rueb as principal accounting officer - stocktitan.net
Tyra Biosciences, Inc. Announces Principal Accounting Officer Changes, Effective April 1, 2026 - marketscreener.com
Tyra Biosciences stock hits all-time high at 39.21 USD By Investing.com - Investing.com South Africa
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59 - 富途牛牛
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Growth Stocks Worth Watching – March 31st - Defense World
Precision Trading with Tyra Biosciences Inc. (TYRA) Risk Zones - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Reaches New 1-Year HighWhat's Next? - MarketBeat
Tyra Biosciences stock hits all-time high at 39.21 USD - investing.com
Tyra Biosciences (NASDAQ:TYRA) Trading 9.8% HigherShould You Buy? - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
Wedbush maintains Tyra Biosciences (TYRA) outperform recommendation - MSN
Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock - MarketBeat
Tyra Biosciences director Kaplan sells shares worth $528k By Investing.com - Investing.com Australia
Tyra Biosciences director Kaplan sells shares worth $528k - Investing.com
Tyra Biosciences (NASDAQ: TYRA) director exercises 67,467 options, sells and returns shares - Stock Titan
Insider plans sale of 53,172 TYRA shares via option exercise (TYRA) - Stock Titan
Piper Sandler reiterates Tyra Biosciences stock rating on oral therapy potential - Investing.com Canada
[144] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com
Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline - openPR.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart
Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Highs Report: Is Tyra Biosciences Inc forming a breakout patternChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Non Muscle Invasive Bladder Cancer Pipeline Expands As 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds Delveinsight CG Oncology, Janssen, Tyra Biosciences, Urogen Pharma - Mena FN
Dabo gratinib designation honors key Tyra Biosciences executives - tradersunion.com
Tyra Biosciences (NASDAQ:TYRA) Trading Down 4.5%Should You Sell? - MarketBeat
Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance - Sahm
Best Growth Stocks To Follow Today – March 20th - Defense World
Piper Sandler Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $56.00 - Defense World
Technical Reactions to TYRA Trends in Macro Strategies - news.stocktradersdaily.com
Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook - Sahm
Cantor Fitzgerald initiates coverage of Tyra Biosciences (TYRA) with overweight recommendation - MSN
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position - AOL.com
Boone Capital Invests in Tyra Biosciences: $10.48M Stake AcquiredNews and Statistics - IndexBox
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool
Piper Sandler Issues Positive Forecast for Tyra Biosciences (NASDAQ:TYRA) Stock Price - MarketBeat
Piper Sandler Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $56 - 富途牛牛
Tyra Biosciences Inc (TYRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tyra Biosciences Inc 주식 (TYRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KAPLAN GILLA | Director |
Mar 25 '26 |
Sale |
36.97 |
14,295 |
528,506 |
28,231 |
0.47%
2.75%
자본화:
|
볼륨(24시간):